ATC Group: R07AX Other respiratory system products

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R07AX in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R07 Other respiratory system products
3 R07A Other respiratory system products
4 R07AX Other respiratory system products

Group R07AX contents

Code Title
R07AX01 Nitric oxide
R07AX02
R07AX30 Ivacaftor and lumacaftor
R07AX31
R07AX32 Ivacaftor, tezacaftor and elexacaftor
R07AX33

Active ingredients in R07AX

Active Ingredient

Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract.

Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations with reduced channel-open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance).

The combined effect of lumacaftor and ivacaftor is increased quantity and function of F508delCFTR at the cell surface, resulting in increased chloride ion transport. The exact mechanisms by which lumacaftor improves cellular processing and trafficking of F508delCFTR and ivacaftor potentiates F508del-CFTR are not known.

Elexacaftor and tezacaftor are CFTR correctors that bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of F508del-CFTR to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Ivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of elexacaftor, tezacaftor and ivacaftor is increased quantity and function of F508del-CFTR at the cell surface, resulting in increased CFTR activity as measured by CFTR mediated chloride transport.

Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the haeme moiety of cytosolic guanylate cyclase. When inhaled, nitric oxide produces selective pulmonary vasodilation.

Related product monographs

Document Type Information Source  
 INOMAX Inhalation gas MPI, EU: SmPC European Medicines Agency (EU)
 KAFTRIO Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 KAFTRIO Granules MPI, EU: SmPC European Medicines Agency (EU)
 KALYDECO Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 KALYDECO Granules MPI, EU: SmPC European Medicines Agency (EU)
 KINOX Inhalation gas MPI, CA: SPM Health Products and Food Branch (CA)
 NEOPHYR Medicinal gas, compressed MPI, EU: SmPC Health Products Regulatory Authority (IE)
 NOXIVENT 101 Inhalation gas MPI, US: SPL/PLR FDA, National Drug Code (US)
 ORKAMBI Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 ORKAMBI Granules MPI, EU: SmPC European Medicines Agency (EU)